One containing casirivimab, one containing imdevimab
Sold as Ronapreve
Every registration of this product has been cancelled.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 2
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Roche Products (Pty) LtdCancelled | Ronapreve | 300 mg/25 ml, 332 mg/11,1 ml 1 | 560909, 560910 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ronapreve 300 mg/25 ML EACH CO-PACK CONTAINS ONE VIAL CONTAINING CASIRIVIMAB 300,0 mg ONE VIAL CONTAINING IMDEVIMAB 300,0 mg | 300 mg/25 ml | 56090956/30.2/0909 | Cancelled | S4 | None |
| Ronapreve 1 332 mg/11,1 ML EACH CO-PACK CONTAINS ONE VIAL CONTAINING CASIRIVIMAB 1 332,0 mg ONE VIAL CONTAINING IMDEVIMAB 1 332,0 mg | 332 mg/11,1 ml 1 | 56091056/30.2/0910 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence medium.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for One vial containing casirivimab, one vial containing imdevimab
S4: Casirivimab
Consolidated Schedules 06 July 2026, line 5681
S4: Imdevimab
Consolidated Schedules 06 July 2026, line 6728
Pharmacological class: Antigens. (class 30.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.